

SUPPLEMENTAL TABLE

Supplementary Table 1. Germline *RAD51B* pathogenic variant carriers in TCGA cohort.

ID	TCGA Case ID	Sex	Tumor type	<i>RAD51B</i> variant	<i>RAD51B</i> mutation type	Mean allele frequency (MAF) in gnomAD	Ethnicity-specific MAF in gnomAD	Age	Hormone receptor status	Ethnicity
TCGA-01	TCGA-A8-A06X ¹	Female	Breast Invasive Ductal Carcinoma	NM_002877.6(RAD51B): c.139C>T(p.Arg47Ter)	Truncating SNV	38/282688 (0.01%)	N/A	77	ER+, PR-, HER2+	N/A
TCGA-02	TCGA-B5-A1N2 ²	Female	Uterine Endometrioid Carcinoma	c.22C>T(p.Arg8Ter)	Truncating SNV	Absent	Absent	70	NP	N/A
TCGA-03	TCGA-E2-A573 ³	Female	Breast Invasive Ductal Carcinoma	c.22C>T(p.Arg8Ter)	Truncating SNV	Absent	Absent	48	ER-, PR-, HER2-	Caucasian
TCGA-04	TCGA-42-2588 ⁴	Female	High-Grade Serous Ovarian Cancer	c.414_418delGGTGT(p.Val139HisfsTer2)	Truncating Indel	Absent	Absent	61	NP	
TCGA-05	TCGA-DD-A3A5 ⁵	Female	Liver Hepatocellular Carcinoma	NM_002877.6(RAD51B): c.139C>T(p.Arg47Ter)	Truncating SNV	38/282688 (0.01%)		66	NP	Caucasian
TCGA-06	TCGA-CD-A4Ml ⁶	Male	Stomach Adenocarcinoma	c.592G>T(p.Glu198Ter)	Truncating SNV	Absent	Absent	62	NP	Caucasian

Abbreviations: TCGA, The Cancer Genome Atlas; gnomAD, The Genome Aggregation Database; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; NP, not performed.


Supplementary Table 2. Sequences for 97-mer oligonucleotides and PCR/sequencing primers used for cloning of miR-E shRNAs:

Oligonucleotide	Sequence
<i>shRenilla</i>	TGCTGTTGACAGTGAGCGCAGGAATTATAATGCTTATCTATAGTGAAGCCACAGATGTATAG ATAAGCATTATAATTCCCTATGCCTACTGCCTCGGA
<i>shRAD51B</i> #1	TGCTGTTGACAGTGAGCGAACCTGTGATGAAGTTCTACAATAGTGAAGCCACAGATGTATTGTA GAACTTCATCACAGGTGTGCCTACTGCCTCGGA
<i>shRAD51B</i> #2	TGCTGTTGACAGTGAGCGCCCCGGCATGGGTAGCAAGAAATAGTGAAGCCACAGATGTATTTCTTGCTACCCATGCCGGTTGCCTACTGCCTCGGA
<i>shRAD51B</i> #3	TGCTGTTGACAGTGAGCGCCCCGGCATGGGTAGCAAGAAATAGTGAAGCCACAGATGTATTTCTTGCTACCCATGCCGGTTGCCTACTGCCTCGGA
<i>shBRCA1</i>	TGCTGTTGACAGTGAGCGCTAGCTGGTTTCCCTAAGTTTATAGTGAAGCCACAGATGTA TAAACTTAGGGAAACCAGCTATTGCCTACTGCCTCGGA
miRE-Xho-fw	TGAACTCGAGAAGGTATATTGCTGTTGACAGTGAGCG
miRE-Eco-rev	TGAACTCGAGAAGGTATATTGCTGTTGACAGTGAGCG
miRE-fwd	TGTTTGAATGAGGCTTCAGTAC

SUPPLEMENTAL FIGURES


Supplementary Figure 1

Large-scale transition (LST) scores in biallelic RAD51B-associated cancers, monoallelic RAD51B-associated cancers, biallelic BRCA1-associated cancers, biallelic BRCA2-associated cancers, and RAD51B wild-type cases with LOH. As LOH events themselves are copy number alterations that could contribute to LST signal, cases harboring RAD51B LOH with a loss-of-function allele were compared to TCGA cases harboring RAD51B LOH with a wild type allele (Mann-Whitney U).




Supplementary Figure 2. Homologous recombination phenotype of *RAD51B* c.139C>T(p.Arg47*) variant.

A) The standard DR-GFP reporter assay established in U2OS cells was used to assess the influence of the NM_002877.6[*RAD51B*]: c.139C>T(p.Arg47*) variant on *RAD51B*-dependent homologous recombination. The c.139C>T(p.Arg47*) variant was unable to complement HR proficiency beyond that observed with expression of an empty vector, in contrast to complementation with wild-type *RAD51B*, which resulted in an approximately two-fold increase in recombination repair. Error bars represent standard error of mean. Student's t-test was used to compare mean GFP% between conditions. B) Corresponding immunoblot of *RAD51B* expression in U2OS cells expressing an inducible shRNA against the 5' UTR of *RAD51B*, and transfected with expression vectors encoding wild-type *RAD51B*, p.Arg47* (NM_002877.6[*RAD51B*]: c.139C>T[p.Arg47*]), or an empty reading frame (EV). Immunoblotting was performed using a monoclonal antibody (Novus NB100-176) raised against full-length *RAD51B* (unknown epitope) which may be unable to detect the truncated p.Arg47* variant. Abbreviations: WT, wild type; EV, empty vector, GFP, green fluorescent protein.





Supplementary Figure 3. Pedigree charts for patients harboring pathogenic germline *RAD51B* variants


MSK_01




Turkey











Puerto Rico















Turkey



Breast 43
RAD51B c.85-2delA
CHEK2 c.592+3A>T (IVS4+3A>T) Uncertain Significance

SUPPLEMENTAL REFERENCES

1. TCGA-A8-A06X *NCI Genomic Data Commons Data Portal* <https://identifiers.org/gdc:70931617-b3df-4a12-8e3f-2b2307602f48>
2. TCGA-B5-A1N2 *NCI Genomic Data Commons Data Portal* <https://identifiers.org/gdc:d79e692c-5053-4484-a180-01a094c5ff45>
3. TCGA-E2-A573 *NCI Genomic Data Commons Data Portal* <https://identifiers.org/gdc:6429c443-8ac3-407f-bb9c-66420b904bbf>
4. TCGA-42-2588 *NCI Genomic Data Commons Data Portal* <https://identifiers.org/gdc:654d02ab-05b4-4863-99d9-04d087ff91b4>
5. TCGA-DD-A3A5 *NCI Genomic Data Commons Data Portal* <https://identifiers.org/gdc:d8549d23-37d4-42bd-b472-f49bbebd09b0>
6. TCGA-CD-A4MI *NCI Genomic Data Commons Data Portal* <https://identifiers.org/gdc:cda6d95c-be6a-485e-ba9a-c57f3eb3f99a>